Arterra Bioscience Spa · MIL:ARBS
Arterra Bioscience Spa — Investor Conference Naples Banca Profilo 2023
27 slides from Arterra Bioscience Spa's conference presentation, Sep 28, 2023
Slide 1: Post IPO 2020-2023 Investor Conference Naples Banca Profilo
POST IPO 2020-2023 Investor Conference Naples Banca Profilo September 28th, 2023
Slide 2: Index
Index TOPICS • ARTERRA AT GLANCE • POST IPO (2020-2023) MARKET CONSOLIDATION & DIVERSIFICATION • FINANCIALS
Slide 3: People Speaking Today
People Speaking Today M. GABRIELLA COLUCCI VINCENZO FOGLIANO GUALTIERO IOIMO Founder, President and CEO Chief Scientific Officer CFO and Investor Relations Manager
Slide 4: Arterra Bioscience - Innovative SME
Arterra Bioscience - Innovative SME Arterra Bioscience Is a biotech company listed on the “Euronext Growth Milan” market of Borsa Italiana since 2019, founded in Naples by M. Gabriella Colucci in 2004 with the aim of developing technologies and innovative solutions that find application in various i
Slide 5: Post IPO 2020-2023
POST IPO 2020 -2023 Investor Conference Naples Banca Profilo September 28th, 2023
Slide 6: Ownership & Company Structure
Ownership & Company Structure Main Shareholders Ing. Giuseppe Ferrante Dr. Gualtiero Ioimo Production Director & CFO, IR Manager & Board member Board member Gabriella Colucci Paolo Colucci 27.9% 7.5% Prof. Lucio Annunziato Indipendent Board member Industrial Shareholders 2021 Employees 8.7% 36 37 14
Slide 7: Arterra Team
Arterra Team Production and R&D Team 1 11 13 7 PhD MSc Lab Technician Chem. Eng. 25 12 The number does not include the administrative workforce (4 employees), warehouse workforce (1 employee) and the PhD and MSc students.
Slide 8: Our facilities
Our facilities Chemistry Lab Plant Cell Culture Lab Microbilogy Lab Moleculaar & Cell Biol Lab Histology & MicroscopyLab Production Lab
Slide 9: Management team
Management team M. GABRIELLA COLUCCI GIUSEPPE FERRANTE ANNALISA TITO CEO COO Cell & Mol Biol. Director VINCENZO FOGLIANO MARIDA BIMONTE MAURA ANGRLILLO CSO Grant & IP Marketing & Sales Director Project Manager
Slide 10: Company organization
mx,_Company organizartion President & CEO Gabriella Colucci Executive Assistant Alexandra Fellermeier Director Marida Bimonte MANAGEMENT TEAM (MT) Grant & IP Office QOOROOE 6606 @ ®O0000O Sea A ArterraBioscience
Slide 11: Research Units
Research Units Chemistry Plant Biology Extraction RU Lyophilizati Histology on Molecular & Cell Biology
Slide 12: Research Units – Case Study
Research Units – Case Study Intercos Vitalab MT MMT MT 3 months research project Vita AvoCare
Slide 13: Certification
moc _ Certification Va EFFCI up CERTIFIED Azienda certificata da ClimatePartner } climate-id.com/RUPASF 2023 ecovadis Sustainability Rating A ArterraBioscience
Slide 14: Innovation in COSMETIC
NEW ACTIVE INGREDIENTS ON THE MARKET Innovation in COSMETIC CONSOLIDATED SEGMENT: SKIN CARE & MAKE-UP 2020-PRESENT NC55 Vita Ray-Immune NC56 Anchoryl Vita NC57 Vita Adren-Align NC59 Vita BotaniGuard. Pelargonium capitatum Scabiosa arvensis Ficus carica Punica granatum plant cells extract plant cells
Slide 15: Innovation in COSMETIC
Innovation in COSMETIC NEW segment: Hair Care 2020-Present Podium presentation: Identification of a novel rejuvenation marker for the hair follicle ecosystem PATENT Uso di estratti di origine vegetale per la stimolazione della crescita dei capelli e composizioni cosmetiche o farmaceutiche contenenti
Slide 16: Scientific Achievement
Scientific Achievement Innovation in COSMETICS 2020-2023 22 Scientific Publications on International Scientific Journals 9 communications to International meetings 6 Patents 16 New products on the market
Slide 17: Regulatory Achievements 2020-2023
Regulatory Achievements 2020- 2023 China State Council released the final version of CSAR on 01 January 2021 and replaced the existing Cosmetics Hygiene Supervision Regulations China’s new cosmetics regulation include many changes: 🧬New cosmetic definitions, scope and classifications 🧬Management…
Slide 18: Innovation in COSMETICS started in 2023
Innovation in COSMETICS started in 2023 Powder active ingredients for make- In collaboration with Intercos New up application Raw Material Group & UNINA In collaboration with University of Delivery Systems* Florence In collaboration with ABR Srl & CRB Extracellular Vescicles EV Benelux Recombinant p
Slide 19: Diversification 2020-2023
Diversification 2020-2023 MEDICAL DEVICE & NUTRACEUTICAL ACNE CONTROL COMMERCIALIZED BY ATOPIC DERMATITIS 102021000020309.Estratti derivati da olive e CLINICAL STUDY pale di fico d’India per l’uso nella prevenzione IN PROGRESS e nel trattamento della dermatite atopica. IRRITABLE BOWEL SYNDROME (IBS)
Slide 20: Diversification 2020-2023
Diversification 2020-2023 AGRIFOOD Co- Development Up-cycling of the mango waste. UNDER EVALUATION BY BABY FOOD BRANDS IN DEVELOPMENT
Slide 21: Diversification Technology 2022 - Present
Diversification TECHNOLOGY 2022 - Presen Pathogen control - New Proprietary Enabling Technology dsRNA Bio-stimulants – Recombinant peptides Fermented foods – Smart Lactobacilli Lactobacillus as a tool for synthetic biology & Precision Fermentation 3 New proprietary registred strains Patent in prepar
Slide 22: Granted Projects
Granted Projects ✓ InnCoCells ✓ SmartLab ✓ Plantform Granted:Horizon 2020 Granted: Region Granted: MISE 2021-2024 2022-2023 2023-2025 Cosmetics Technology Agrifood Cosmetics Environment Nutraceuticals Medical Device PLANT CELLS AND TISSUES PLANT CELL CULTURE LATTOBACILLUS SP AS BIOFACTORY ACTIVE ING
Slide 23: Financials
FINANCIALS Investor Conference Naples Banca Profilo September 28th, 2023
Slide 24: Economic results as of December 31, 2022
Economic results as of December 31, 2 Value of Production (€/000) Ebitda (€/000) Net Income (€/000) 26,7% 5.303 4.608 40,2% 24,1% 498 37,7% 25,7% 1.414 4.309 37,2% 2.133 136 917 1.242 1.109 1.111 1.351 1.735 1.602 3.825 3.564 2.822 -134 2020 2021 2022 2020 2020 2021 2022 2021 2022 Changes in finishe
Slide 25: Limited production costs driving profitability
Limited production costs driving compelling profitability: thriving upside arising from additional revenues to be mostly converted in EBITDA Turnover (€/000) Ebitda (€/000) Net Income (€/000) 2.766 43,5% 256 35,1% 1.205 2.066 2.119 384 24,5% 510 659 31% 18.9% 679 641 17,3% 391 11,7% 2.126 366 249 1.
Slide 26: Net Debt / Equity
Net Debt / Equity Net Debt (€/000) Equity (€/000) 10.467 2021 2022 1H 2023 10.050 Cash and Cash Equivalents (4.814) (4.393) (4.337) Current Financial 9.473 Receivables - - - 891 Financial assets other 1.823 than fixed assets (1.598) (1.671) Current Financial Debt 223 174 136 Current Net Debt (4.591)
Slide 27: Thank You!
Investor Conference Naples Banca Profilo THANK YOU!
Arterra Bioscience — Investor Conference Naples Banca Profilo 2023 on 6ix